Edition:
India

Ajanta Pharma Ltd (AJPH.NS)

AJPH.NS on National Stock Exchange of India

1,686.70INR
12:59pm IST
Change (% chg)

Rs-33.80 (-1.96%)
Prev Close
Rs1,720.50
Open
Rs1,716.10
Day's High
Rs1,731.40
Day's Low
Rs1,671.10
Volume
68,097
Avg. Vol
174,411
52-wk High
Rs2,125.00
52-wk Low
Rs1,399.30

AJPH.NS

Chart for AJPH.NS

About

Ajanta Pharma Limited is a holding company. The Company is a specialty pharmaceutical company engaged in developing, producing and marketing a range of branded and generic formulations. Its business includes branded generics in emerging markets of Asia and Africa, generics in the developed markets of the United States and... (more)

Overall

Beta: 1.28
Market Cap(Mil.): Rs151,412.59
Shares Outstanding(Mil.): 88.00
Dividend: 7.00
Yield (%): 0.76

Financials

  AJPH.NS Industry Sector
P/E (TTM): 30.26 29.09 30.04
EPS (TTM): 56.85 -- --
ROI: -- 13.81 13.33
ROE: -- 14.74 14.48

BRIEF-Ajanta Pharma's Dahej facility does not get form 483 after FDA inspection

* Ajanta Pharma Ltd says co's Dahej facility was inspected by FDA from April 3-7, 2017; no form 483 was issued Source text: [This is to inform you that Company's formulation facility at Dahej was inspected by US FDA from 3rd to 7th April, 2017. At the end of the inspection, no Form 483 was issued to the Company] Further company coverage:

10 Apr 2017

BRIEF-Ajanta Pharma's Paithan facility been issued one procedural related 483 by USFDA

* Says company's Paithan facility was recently inspected by US FDA and company has issued one procedural related 483.

09 Feb 2017

BRIEF-Ajanta Pharma Dec-qtr consol net profit rises

* Dec quarter consol net profit 1.43 billion rupees versus profit 1.14 billion rupees year ago

24 Jan 2017

BUZZ-India's Ajanta Pharma slumps to over 6-1/2-month low over U.S. FDA drug ban

** Ajanta Pharma Ltd dives as much as 14.55 pct to 1,526.65 rupees, lowest since July 4, 2016

24 Jan 2017

BRIEF-Ajanta Pharma says haven't received any import alert by US FDA

* Ajanta Pharma clarifies on import alert received from USFDA

24 Jan 2017

BRIEF-Ajanta Pharma gets import alert from USFDA for its Aurangabad plant - FDA website

* Gets import alert from USFDA for its Aurangabad plant - FDA website

24 Jan 2017

BRIEF-Ajanta Pharma gets USFDA nod for Duloxetine Hydrochloride delayed release capsules

* Says Ajanta Pharma announces US FDA approval for Duloxetine Hydrochloride delayed release capsules

09 Jan 2017

BRIEF-Ajanta Pharma launches Voriconazole tablets in U.S.

* Ajanta pharma usa - launch of voriconazole tablets (50mg, 200mg), a bioequivalent generic version of Vfend into us market Source text for Eikon: Further company coverage:

07 Nov 2016

More From Around the Web

Earnings vs. Estimates